ative Medicine (CIRM). The CIRM award fully pays for the road of our allogeneic Coif-the-shelf) E-CEL UVEC program reaching the clinic trial stage. E-CEL UVEC is being developed for curative treatment for blood cancers and advancing gene therapy for multiple inherited diseases. Assuming continued success,